PF614 capsule + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Postoperative Pain, Acute
Conditions
Postoperative Pain, Acute
Trial Timeline
Dec 9, 2025 → Nov 1, 2026
NCT ID
NCT06602271About PF614 capsule + Placebo
PF614 capsule + Placebo is a phase 3 stage product being developed by Ensysce Biosciences for Postoperative Pain, Acute. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06602271. Target conditions include Postoperative Pain, Acute.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06602271 | Phase 3 | Recruiting |
Competing Products
20 competing products in Postoperative Pain, Acute